Dose-Dependent Anti-Inflammatory and Neuroprotective Effects of an ανβ3 Integrin-Binding Peptide

Figure 7

C16 treatment ameliorated the disease progression and alleviated the disease severity. ((a)–(c)) The clinical progression of EAE was attenuated after medium (b) and high (c) dose C16 applications. ^a𝑃<0.05 versus vehicle treated group at the same time point. ^aa𝑃<0.01 versus vehicle treated group at the same time point. (d) The clinical progression of EAE was attenuated by the C16 late treatment. ^a𝑃<0.05 versus vehicle treated group at the same time point.

(a)

(b)

(c)

(d)